Investigations have been extended to anti-CTLA-4 therapy which, when combined with rapamycin and an anti-cancer vaccine in vivo in mice, resulted in CD8+ T-cell expansion, IFN-γ production and differentiation towards a memory phenotype as well as featuring enhanced FA metabolism and an increased respiratory capacity [290]. Here, CD8A is linked to cancer.